Technology | Artificial Intelligence | February 15, 2018

Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning

Initial launch will include liver and lung artificial intelligence oncology software to empower clinicians to quickly measure and track lesions and nodules in MRI and CT scans

Arterys Receives First FDA Clearance for Oncology Imaging Suite With Deep Learning

February 15, 2018 — Arterys Inc. announced its fifth 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the Arterys Oncology AI Suite, an artificial intelligence (AI)-based, cloud-based medical imaging software.

The new oncology software complements Arterys’ existing web-based offering, and helps clinicians measure and track tumors or potential cancers, and easily apply radiological standards. The initial deep learning workflows will be for liver magnetic resonance imaging (MRI) and computed tomography (CT) scans, as well as for lung CT scans. With this new technology, radiologists can now easily confirm, evaluate, quantify, and report on the absence or presence of lung nodules and liver lesions along with their key characteristics using a simple web browser. The company plans additional deep learning workflows for solid tumors in other organs.

"The evaluation of primary and metastatic disease in the lung and liver are among the most valuable contributions of radiologists to the care of patients with cancer," said radiologist and Arterys co-founder Albert Hsiao, M.D., Ph.D. "We desperately need more efficient technology to automatically track lung and liver lesions to further improve diagnosis, assess response to treatment, and automate reporting with standardized terminology including Lung-RADS and LI-RADS."

Oncology AI runs on the Arterys MICA (Medical Imaging Cloud AI) platform, which the company said is easier to deploy than on-premise imaging systems and complies with patient data privacy and security requirements in 27 countries. The software uses deep learning to automate the segmentation of lung nodules and liver lesions, with accuracy equal to segmentations performed manually by experienced clinicians. The clinician has the capability to edit these automated segmentations, so they always remain in control.

For more information: www.arterys.com

Related Artificial Intelligence Content

Arterys Receives FDA Clearance for Arterys MICA Web-Based Medical Imaging Analytics Platform

Arterys Partners with GE Healthcare to Launch Viosworks Cardiac Imaging Platform

Arterys Showcases FDA-cleared 4D Flow MRI Software at RSNA 2016

Arterys Cardio DL Cloud MRI Analytics Software Receives FDA Clearance

VIDEO: Editor’s Choice of Most Innovative New Technologies at RSNA 2016

Related Content

FDA Clears GE's Deep Learning Image Reconstruction Engine
Technology | Computed Tomography (CT) | April 19, 2019
GE Healthcare has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) of its Deep Learning Image...
In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images

In a demonstration on the exhibit floor of the SBI symposium, Koios software identified suspicious lesions in ultrasound images. Photo by Greg Freiherr

Feature | Artificial Intelligence | April 19, 2019 | By Greg Freiherr
Commercial efforts to develop...
Artificial Intelligence Performs As Well As Experienced Radiologists in Detecting Prostate Cancer
News | Artificial Intelligence | April 18, 2019
University of California Los Angeles (UCLA) researchers have developed a new artificial intelligence (AI) system to...
Videos | Breast Imaging | April 18, 2019
In a keynote lecture at the Society of Breast Imaging (SBI)/American College of Radiology (ACR) 2019 Symposium, ...
Atrium Health Debuts Amazon Alexa Skill to Help Patients Access Medical Care
News | Artificial Intelligence | April 18, 2019
Atrium Health patients will now be able to use Amazon’s electronic voice system Alexa to not only locate the nearest...
Oxipit Introduces Multilingual Support for ChestEye AI Imaging Suite
News | Artificial Intelligence | April 16, 2019
The CE-certified ChestEye artificial intelligence (AI) imaging suite by Oxipit is now available in seven European...
iCAD Appoints Stacey Stevens as President
News | Radiology Business | April 16, 2019
iCAD Inc. recently announced that Stacey Stevens has been named president. As president, Stevens will have expanded...
Ebit and DiA Imaging Analysis Partner on AI-based Cardiac Ultrasound Analysis
News | Cardiovascular Ultrasound | April 16, 2019
DiA Imaging Analysis has partnered with the Italian healthcare IT company Ebit (Esaote Group), to offer DiA’s LVivo...